Get the Stockscreener App
6.51
5.51%
0.34
After Hours:
6.73
0.22
+3.38%
Fennec Pharmaceuticals Inc stock is traded at $6.51, with a volume of 463.51K.
It is up +5.51% in the last 24 hours and down -24.39% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$6.17
Open:
$6.1
24h Volume:
463.51K
Relative Volume:
2.76
Market Cap:
$222.40M
Revenue:
$38.79M
Net Income/Loss:
$-6.57M
P/E Ratio:
-27.35
EPS:
-0.238
Net Cash Flow:
$-8.52M
1W Performance:
-14.90%
1M Performance:
-24.39%
6M Performance:
-27.99%
1Y Performance:
+0.62%
1-Day Range:
$6.062
$6.67
1-Week Range:
$5.90
$7.6597
52-Week Range:
$4.68
$9.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
6.51 | 210.79M | 38.79M | -6.57M | -8.52M | -0.238 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | B. Riley Securities | Buy |
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
View All
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec (NASDAQ: FENC) CFO exercises 13,072 stock options in Form 4 - Stock Titan
Fennec (NASDAQ: FENC) Chief Strategy Officer exercises options, holds 145,300 shares - Stock Titan
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2025 Earnings Call Transcript - Insider Monkey
Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Can Afford To Invest In Growth - Yahoo Finance
Fennec Pharmaceuticals Hits Day Low of CAD 8.26 Amid Price Pressure - Markets Mojo
Fennec Pharmaceuticals Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Day Trade: Will Fennec Pharmaceuticals Inc benefit from AI trendsEarnings Summary Report & Short-Term High Return Ideas - baoquankhu1.vn
Adherex Technologies (FENC) to Release Earnings on Wednesday - Defense World
Fennec Pharmaceuticals Reports Record 2025 PEDMARK® Sales Growth and Financial Results, Highlights Pipeline and Global Expansion - Minichart
(FENC) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Fennec Pharmaceuticals Reports Record FY2025 Net Product Sales of $44.6M, Q4 Sales $13.8M - TradingView
Record PEDMARK growth but wider 2025 loss for Fennec (NASDAQ: FENC) - Stock Titan
Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada
Fennec Pharmaceuticals misses Q4 estimates on earnings and revenue - MSN
Adherex Technologies Q4 2025 Earnings Call Transcript - MarketBeat
Earnings Call Summary | Fennec Pharmaceuticals(FENC.US) Q4 2025 Earnings Conference - Moomoo
Adherex Technologies Q4 Earnings Call Highlights - MarketBeat
Adherex Technologies (NASDAQ:FENC) Announces Earnings Results - MarketBeat
Earnings call transcript: Fennec Pharmaceuticals Q4 2025 misses expectations - Investing.com
Craig-Hallum Maintains Fennec Pharmaceuticals(FENC.US) With Buy Rating - Moomoo
Fennec Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Fennec Pharmaceuticals posts fiscal year 2025 financial results and business update - Traders Union
Fennec Pharmaceuticals Inc. (FENC) Misses Q4 EPS Estimates - AlphaStreet
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Fennec Pharmaceuticals (NASDAQ:FENC) Reports Q4 2025 Revenue Growth but Misses Earnings Estimates - ChartMill
Fennec Pharmaceuticals Posts Record PEDMARK Sales and Broadens Clinical Footprint in 2025 - TipRanks
FENNEC PHARMACEUTICALS ($FENC) Releases Q4 2025 Earnings - Quiver Quantitative
Fennec Pharmaceuticals misses Q4 estimates on earnings, revenue By Investing.com - Investing.com Australia
Fennec Pharmaceuticals misses Q4 estimates on earnings, revenue - Investing.com UK
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Cancer hearing-loss drug lifts Fennec sales 50% as debt hits zero - Stock Titan
Fennec Pharmaceuticals earnings are imminent; these most accurate analysts revise forecasts ahead of earnings call - MSN
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
FRX.CA Forecast, Price Target & Analyst Ratings | FENNEC PHARMACEUTICALS INC (TSX:FRX) - ChartMill
Fennec Pharmaceuticals (TSX:FRX) Shares Drift Below Key Average Level - Kalkine Media
Fennec Pharma (TSX:FRX) Falls Below Key Average in TSX Index - Kalkine Media
Fennec to Report 2025 Results as Global Rollout of PEDMARK Advances - The Globe and Mail
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat
Retail Surge: Is Fennec Pharmaceuticals Inc still a buy after recent gains2026 Big Picture & Reliable Trade Execution Plans - baoquankhu1.vn
Breakout Zone: Can Fennec Pharmaceuticals Inc stock outperform in a bear marketTrend Reversal & Long-Term Capital Growth Ideas - baoquankhu1.vn
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026 - The Manila Times
Fennec Pharmaceuticals Inc. - Mena FN
Fennec schedules March 24 call to unveil full-year 2025 numbers - Stock Titan
Cipla To Hold Off On Pediatric Cancer Drug Generic Until 2033 - Law360
B Riley Reaffirms Fennec's Buy Rating, US$16.00 Price Target After Cipla Settlement - marketscreener.com
Fennec settles patent case with Cipla over generic PEDMARK By Investing.com - Investing.com Australia
FENC Stock Quote - RichTv
Fennec Pharmaceuticals (FENC) delays Cipla generic PEDMARK rival until 2033 - Stock Titan
Fennec Pharmaceuticals announces settlement agreement resolving Pedmark patent litigation - marketscreener.com
Fennec settles patent case with Cipla over generic PEDMARK - Investing.com
Fennec Pharmaceuticals Announces Settlement Agreement Resolving Pedmark Patent Litigation - TradingView
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):